- As Novo Nordisk begins PhII sickle cell trial, it snags a later-stage blood disorder drug in $1.1B Forma buy Endpoints News
- Novo Nordisk plows $1.1B for Forma Therapeutics with eye on SCD FierceBiotech
- Forma Therapeutics Shares Surge on Takeover by Novo Nordisk Morningstar
- Novo Nordisk to Buy Forma Therapeutics in $1.1 Billion Deal Bloomberg
- Forma Therapeutics to be acquired by Novo Nordisk in a cash deal valued at $1.1 billion MarketWatch
- View Full Coverage on Google News
As Novo Nordisk begins PhII sickle cell trial, it snags a later-stage blood disorder drug in $1.1B Forma buy – Endpoints News
